Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

NCT05834582 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: Fluzoparib+Paclitaxel
DRUG: Epirubicin+Cyclophosphamide

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]